The stem cell therapy for diabetes and related conditions pipeline analysis report includes ongoing clinical and non-clinical trends in the global stem cell therapy for diabetes and related conditions treatment. Most of the pipeline therapeutics are in early stage of development, a long-lasting and less frequent dose can impact overall diabetes market.
In 2015, the American Diabetes Association (ADA) estimated that the annual total cost of diabetic patients is $223.5 billion in the US alone. The global annual cost is estimated at $465 billion and is expected to reach $510 billion a year by 2030.
Covered in this report
The report covers the present scenario and the growth prospects of the stem cell therapy for diabetes and related conditions. The report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.
Technavio's Stem Cell Therapy for Diabetes and Related Conditions - A Pipeline Analysis Report, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects during the forecast period. The report also includes a discussion of the key companies operating in this market.
- Caladrius Biosciences
- Novo Nordisk
- How will the market evolve during the forecast period?
- What are the major parameters impacting the market?
- What are the key market trends?
- What are the challenges to market growth?
- Who are the key companies in this market space?
PART 02: SCOPE OF THE REPORT
PART 03: STEM CELL THERAPY FOR DIABETES AND RELATED CONDITIONS: AN INSIGHT
PART 06: COMPARATIVE ANALYSIS
- Mid-stage molecules (Phase II)
- Early-stage molecules (Phase I/II)
- Pre-clinical stage molecules
- Inactive and discontinued molecules
PART 08: THERAPEUTIC ASSESSMENT BY THERAPY TYPE
PART 09: THERAPEUTIC ASSESSMENT BY ROA
PART 10: KEY COMPANIES
- Active companies: Category and parameters
- List of abbreviations
Exhibit 01: Drug approval process by US FDA
Exhibit 02: Active pipeline molecules by vendors
Exhibit 03: Pipeline landscape
Exhibit 04: Pipeline molecules by numbers
Exhibit 05: Pipeline molecules by percentage
Exhibit 06: Overview: ALLO-ASC-DFU
Exhibit 07: Clinical trials description of ALLO-ASC-DFU
Exhibit 08: Overview: MPC-300-IV
Exhibit 09: Clinical trials description of MPC-300-IV
Exhibit 10: Overview: CLBS 03
Exhibit 11: Clinical trials description of CLBS 03
Exhibit 12: Overview: PDA-002
Exhibit 13: Clinical trials description of PDA-002
Exhibit 14: Overview: PEC-Encap (VC-01)
Exhibit 15: Clinical trials description of PEC-Encap (VC-01)
Exhibit 16: Overview: PEC-Direct (VC-02)
Exhibit 17: Clinical trials description of PEC-Direct (VC-02)
Exhibit 18: Overview: NSI-566
Exhibit 19: Overview: VC-03
Exhibit 20: Overview: VC-04
Exhibit 21: Overview: MultiStem
Exhibit 22: Overview: Research Program
Exhibit 23: Overview: Diabetes beta cell therapy
Exhibit 24: Overview: Cell therapy for diabetes
Exhibit 25: Overview: Cell therapy for diabetes
Exhibit 26: Overview: Cell therapy for diabetes
Exhibit 27: Overview: ProTrans
Exhibit 28: Inactive molecules
Exhibit 29: Discontinued molecule
Exhibit 30: Analysis by indication
Exhibit 31: Overview of indications
Exhibit 32: Assessment of pipeline products by therapy
Exhibit 33: Assessment of pipeline products by RoA
Exhibit 34: Active companies: Category and parameters 2017
Exhibit 35: Segmentation of companies
Exhibit 36: Overview: Anterogen 2017
Exhibit 37: Overview: Athersys 2017
Exhibit 38: Overview: Caladrius Biosciences 2017
Exhibit 39: Overview: Cellular Therapeutics 2017
Exhibit 40: Overview: Islexa 2017
Exhibit 41: Overview: Kadimastem 2017
Exhibit 42: Overview: Mesoblast 2017
Exhibit 43: Overview: Neuralstem 2017
Exhibit 44: Overview: NextCell Pharma 2017
Exhibit 45: Overview: Novo Nordisk 2017
Exhibit 46: Overview: Orgenesis 2017
Exhibit 47: Overview: Sanofi 2017
Exhibit 48: Overview: ViaCyte 2017
The author of the report recognizes the following companies in the stem cell therapy for diabetes and related conditions: Athersys, Mesoblast, Caladrius Biosciences, Sanofi, and Novo Nordisk.
The “Stem cell therapy for diabetes and related conditions - A pipeline analysis report, 2017” provides comprehensive insights about pipeline molecules in this approach of treatment. The key objective of the report is to establish the understanding of all the pipeline molecules that fall under stem cell therapy for diabetes and related conditions.
This report provides information on the therapeutic development based on the stem cell therapy for diabetes and related conditions dealing with all the pipeline drugs; comparative analysis at various stages covering Phase II, Phase I/II, and pre-clinical; therapeutics assessment by monotherapy and combination products; and molecule type drug information. The report also covers the company’s information involved in the therapeutic development of the products. It also highlights the discontinued and dormant products.
Diabetes is a metabolic disorder. It is a chronic condition associated with high sugar (glucose) level in the blood. Insulin, a hormone produced by the pancreas of the body, lowers the glucose level in the blood. Any defect in insulin secretion, or its action, or both, causes abnormal blood glucose level. Diabetes can be classified into two types, type 1 (insulin-dependent diabetes mellitus or juvenile onset) and type 2 (non-insulin-dependent diabetes mellitus, or adult-onset diabetes). In type 1 diabetes, the body does not produce insulin. In type 2 diabetes, which is the more common type (90%-95%), the body does not make or use insulin well. It can affect all people, regardless of age and sex.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry.